Please refer to biography on website: ethicannpharma.us. A full resume is also available. Regarding my expertise, I have developed a skill set that is well-suited to the development and success of start-ups, including MGI Pharma, MOGEN International (Netherlands) and Sleep Number, to name a few. My key functional skills are finance/financing, strategy, busdev and talent selection. I also have my share of start-up scars--always learning.

Dr. Mackler is a renowned regulatory affairs strategist, having 25 + years’ experience as an FDA attorney on issues related to FDA, EMA and Health Canada, including active preparation of INDs and NDAs involving meetings with global regulatory authorities. His activities now center around advising companies as a board member, venture partner and investor.
A full CV is also available.

Dr. Price has 35 years of experience in biopharma. He has been a co-founder and/or CEO of a number of biopharma start-ups. A Ph.D. in biophysics, he teaches entrepreneurism at several universities, and sits on several biopharma and other high-tech boards. His pharma experience is broad, involving responsibilities for drug manufacturing, testing, quality assurance, marketing, sales and business development for small and large companies.

Dr. Elben has 20+ years’ experience in international pharmaceutical development in both emerging and major companies. He was previously with Axxima Pharmaceuticals, Vertex Pharmaceuticals and Avant Pharmaceuticals obtaining market approvals in the U.S., Asia and Europe. Dr. Elben’s expertise and wide-ranging knowledge base includes running pre-clinical and clinical operations, with successful prosecution of INDs and NDAs.

Mr. Lashyn has 30 years in public and private debt and equity markets. He is Managing Director & VP of Quantico Capital Corp (Calgary, Alberta). He has held advisory positions for companies in the biotech, real estate, and oil & gas industries. He served on the board of CanniMed Therapeutics, a medical products firm and the first Canadian cannabis licensee. Three other EPI co-founders were board members of CanniMed prior to Aurora Cannabis sale.

Mr. Maruoka is a director & partner in ToroVerde Inc., a private equity & venture capital firm (Toronto, Canada). He previously was Managing Director & Equity Research Analyst at Canaccord Genuity, covering healthcare and building Canaccord into the leading cannabis sector global equity research franchise. He was named #1 Analyst in Canada for Biotech and Pharma (Brendan Wood Int’l–2017). Mr. Maruoka holds a MSc. in physiology & molecular bio.